Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
2005 2
2008 2
2009 1
2010 1
2011 1
2012 1
2013 3
2014 1
2015 1
2016 1
2017 1
2018 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
Wang SY, Holzhey T, Heyn S, Zehrfeld T, Fricke S, Hoffmann FA, Becker C, Braunert L, Edelmann T, Paulenz I, Hitzschke M, Flade F, Schwarzer A, Fenchel K, Franke GN, Vucinic V, Jentzsch M, Schwind S, Hell S, Backhaus D, Lange T, Niederwieser D, Scholz M, Platzbecker U, Pönisch W. Wang SY, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2023 Jul;149(7):3739-3752. doi: 10.1007/s00432-022-04184-x. Epub 2022 Aug 20. J Cancer Res Clin Oncol. 2023. PMID: 35987926 Free PMC article.
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M. Holzhey T, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2021 Aug;147(8):2349-2359. doi: 10.1007/s00432-020-03504-3. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433659 Free PMC article.
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Pönisch W. Beck J, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-2553. doi: 10.1007/s00432-017-2504-5. Epub 2017 Aug 21. J Cancer Res Clin Oncol. 2017. PMID: 28828689 Clinical Trial.
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Pönisch W, Holzvogt B, Plötze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa T, Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D. Pönisch W, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2014 Nov;140(11):1947-56. doi: 10.1007/s00432-014-1737-9. Epub 2014 Jun 19. J Cancer Res Clin Oncol. 2014. PMID: 24942335
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al-Ali HK, Jäkel N, Niederwieser D. Pönisch W, et al. Among authors: hoffmann fa. Br J Haematol. 2013 Jul;162(2):202-9. doi: 10.1111/bjh.12361. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692564 Free article. Clinical Trial.
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Pönisch W, Moll B, Bourgeois M, Andrea M, Schliwa T, Heyn S, Schmalfeld M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Egert M, Stiegler R, Krahl R, Remane Y, Bachmann A, Lindner T, Weidhase L, Petros S, Fricke S, Vucinic V, Al Ali H, Niederwieser D. Pönisch W, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2013 Nov;139(11):1937-46. doi: 10.1007/s00432-013-1513-2. Epub 2013 Sep 18. J Cancer Res Clin Oncol. 2013. PMID: 24046251
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AlAli HK, Niederwieser D. Poenisch W, et al. Among authors: hoffmann fa. J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15. J Cancer Res Clin Oncol. 2015. PMID: 25976868
17 results